National Rare Diseases Registry System of China and Related Cohort Studies: Vision and Roadmap

被引:23
作者
Feng, Shi [1 ]
Liu, Shuang [1 ]
Zhu, Chong [2 ,3 ]
Gong, Mengchun [2 ,4 ]
Zhu, Yicheng [2 ,5 ]
Zhang, Shuyang [2 ,5 ]
机构
[1] Peking Union Med Coll, Beijing, Peoples R China
[2] Natl Rare Dis Registry Syst China, Beijing, Peoples R China
[3] Digital China Hlth Technol Co Ltd, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Rare Dis Res Ctr, Beijing, Peoples R China
[5] Peking Union Med Coll Hosp, Beijing, Peoples R China
关键词
rare diseases; patient registry; cohort study; medical informatics; genomics; HUMAN PHENOTYPE ONTOLOGY; ORPHAN DRUGS; DISCOVERY; DIAGNOSIS;
D O I
10.1089/hum.2017.215
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Rare diseases are major challenges in healthcare and medical research and are the basis of national development strategies in many countries. However, inadequate definition of rare diseases and lags in orphan drug development in China hinder rare disease research. In response, the first National Rare Diseases Registry System of China (NRDRS) was established, and various cohort studies have been launched since 2016. More than 20 top academic institutions in China are currently participating in this joint effort to carry out nationwide registration of rare diseases. The primary objectives are to establish standardization for the registration platform, build biobanks of genomic data, and create partnerships for data sharing and research collaboration. Innovative informatics technologies have been implemented to develop the NRDRS, including employment of ontological and knowledge bases to render standardization and support standard of care. Development of informatics analysis tools will facilitate accurate and more efficient diagnoses for rare diseases. Long-term research collaboration is encouraged to create additional national rare disease networks for research translation and to benefit patients with rare diseases. The NRDRS of China and related cohort studies are anticipated to enlighten rare disease research significantly in China.
引用
收藏
页码:128 / 135
页数:8
相关论文
共 44 条
[1]   Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support [J].
Anderson, Matilda ;
Elliott, Elizabeth J. ;
Zurynski, Yvonne A. .
ORPHANET JOURNAL OF RARE DISEASES, 2013, 8
[2]   Socio-economic burden of rare diseases: A systematic review of cost of illness evidence [J].
Angelis, Aris ;
Tordrup, David ;
Kanavos, Panos .
HEALTH POLICY, 2015, 119 (07) :964-979
[3]   An informatics approach to analyzing the incidentalome [J].
Berg, Jonathan S. ;
Adams, Michael ;
Nassar, Nassib ;
Bizon, Chris ;
Lee, Kristy ;
Schmitt, Charles P. ;
Wilhelmsen, Kirk C. ;
Evans, James P. .
GENETICS IN MEDICINE, 2013, 15 (01) :36-44
[4]   Preserving an integrated view of informatics [J].
Bernstam, Elmer V. ;
Tenenbaum, Jessica D. ;
Kuperman, Gilad J. .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2014, 21 (E1) :E178-E179
[5]   Rare-disease genetics in the era of next-generation sequencing: discovery to translation [J].
Boycott, Kym M. ;
Vanstone, Megan R. ;
Bulman, Dennis E. ;
MacKenzie, Alex E. .
NATURE REVIEWS GENETICS, 2013, 14 (10) :681-691
[6]   Towards government-funded special biomedical research programs to combat rare diseases in China [J].
Chen, Kai ;
Yao, Lan ;
Liu, Zhiyong .
BIOSCIENCE TRENDS, 2015, 9 (02) :88-90
[7]   Next generation sequencing: Coping with rare genetic diseases in China [J].
Cram, David S. ;
Zhou, Daixing .
INTRACTABLE & RARE DISEASES RESEARCH, 2016, 5 (03) :140-144
[8]   A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs [J].
Cui, Yazhou ;
Han, Jinxiang .
ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
[9]  
de Lusignan Simon, 2011, Inform Prim Care, V19, P3
[10]   Financing drug discovery for orphan diseases [J].
Fagnan, David E. ;
Gromatzky, Austin A. ;
Stein, Roger M. ;
Fernandez, Jose-Maria ;
Lo, Andrew W. .
DRUG DISCOVERY TODAY, 2014, 19 (05) :533-538